Tag: Als

In 1995, Riluzole (marketed as Rilutek) became the first FDA-approved medication for the treatment of Amyotrophic Lateral Sclerosis (ALS). The medication works primarily by inhibiting the activity of glutamate, a major excitatory neurotransmitter in the central nervous system. By interfering with glutamatergic signaling, the drug helps to reduce the neurotoxicity believed to contribute to the progressive nerve cell damage seen in ALS.

Approved by the FDA in 1995, riluzole was the first drug available for treating amyotrophic lateral sclerosis (ALS) and is one of the only medications shown to slow the disease's progression [1.8.4, 1.8.5]. So, **what is the pharmacology and mechanism of action of riluzole** that grants it this neuroprotective effect?

Affecting a significant number of adults, muscle weakness is a complex symptom stemming from various underlying conditions, making it crucial to receive an accurate diagnosis before determining what medication is good for leg weakness. Unlike a simple ache, leg weakness requires a targeted approach, as effective treatment is directly tied to addressing the root cause, whether it is neurological, muscular, or inflammatory in nature.

Tofersen, an antisense oligonucleotide marketed as Qalsody, was approved by the FDA for the treatment of SOD1-ALS, a rare and devastating form of amyotrophic lateral sclerosis. Like all potent medications, it is associated with a range of potential side effects, from common discomforts to serious neurological complications.